A phase IV, 2x2 factorial, double blind study of 48 versus 96 weeks of PEGASYS 180 microg, with or without 24 weeks of entecavir in adult patients with HBeAg negative chronic hepatitis B.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 25 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by Roche.
- 23 Aug 2010 New trial record
- 13 Aug 2010 Actual end date (Nov 2014) added as reported by ClinicalTrials.gov.